Hydroxychloroquine: A double‑edged sword (Review)
- Authors:
- Rongxiu Huo
- Chengcheng Wei
- Yanting Yang
- Jinying Lin
- Xinxiang Huang
-
Affiliations: Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Autonomous Region 530016, P.R. China - Published online on: February 19, 2025 https://doi.org/10.3892/mmr.2025.13467
- Article Number: 102
-
Copyright: © Huo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Rolain JM, Colson P and Raoult D: Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents. 30:297–308. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P and Khamashta MA: Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review. Ann Rheum Dis. 69:20–28. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Khraishi MM and Singh G: The role of anti-malarials in rheumatoid arthritis-the American experience. Lupus. 5 (Suppl 1):S41–S44. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Demarchi J, Papasidero S, Medina MA, Klajn D, Moral RC, Rillo O, Martiré V, Crespo G, Secco A, Pellet AC, et al: Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy. Clin Rheumatol. 36:2455–2460. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, Cuadrado MJ, Dörner T, Ferrer-Oliveras R, Hambly K, et al: EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 78:1296–1304. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kerrigan SA and McInnes IB: Reflections on ‘older’ drugs: Learning new lessons in rheumatology. Nat Rev Rheumatol. 16:179–183. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Schrezenmeier E and Dörner T: Mechanisms of action of hydroxychloroquine and chloroquine: Implications for rheumatology. Nat Rev Rheumatol. 16:155–166. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Nirk EL, Reggiori F and Mauthe M: Hydroxychloroquine in rheumatic autoimmune disorders and beyond. EMBO Mol Med. 12:e124762020. View Article : Google Scholar : PubMed/NCBI | |
|
McInnes IB and Schett G: Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 7:429–442. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Wirestam L, Arve S, Linge P and Bengtsson AA: Neutrophils-important communicators in systemic lupus erythematosus and antiphospholipid syndrome. Front Immunol. 10:27342019. View Article : Google Scholar : PubMed/NCBI | |
|
Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, Boletis J, Bruce IN, Cervera R, Doria A, et al: EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 83:15–29. 2023. View Article : Google Scholar | |
|
Abd Rahman R, Tun KM, Atan IK, Said MS, Mustafar R and Zainuddin AA: New benefits of hydroxychloroquine in pregnant women with systemic lupus erythematosus: A retrospective study in a tertiary centre. Rev Bras Ginecol Obstet. 42:705–711. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kerschbaumer A, Sepriano A, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, McInnes IB, Bijlsma JWJ, Burmester GR, de Wit M, et al: Efficacy of pharmacological treatment in rheumatoid arthritis: A systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 79:744–759. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ramos-Casals M, Brito-Zerón P, Bombardieri S, Bootsma H, De Vita S, Dörner T, Fisher BA, Gottenberg JE, Hernandez-Molina G, Kocher A, et al: EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. Ann Rheum Dis. 79:3–18. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wolstencroft PW, Casciola-Rosen L and Fiorentino DF: Association between autoantibody phenotype and cutaneous adverse reactions to hydroxychloroquine in dermatomyositis. JAMA Dermatol. 154:1199–1203. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Rees F, Doherty M, Grainge MJ, Lanyon P and Zhang W: The worldwide incidence and prevalence of systemic lupus erythematosus: A systematic review of epidemiological studies. Rheumatology (Oxford). 56:1945–1961. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Jung H, Bobba R, Su J, Shariati-Sarabi Z, Gladman DD, Urowitz M, Lou W and Fortin PR: The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 62:863–868. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu CY, Lin YS, Su YJ, Lin HF, Lin MS, Syu YJ, Cheng TT, Yu SF, Chen JF and Chen TH: Effect of long-term hydroxychloroquine on vascular events in patients with systemic lupus erythematosus: A database prospective cohort study. Rheumatology (Oxford). 56:2212–2221. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senécal JL, Cividino A, Danoff D, Osterland CK, Yeadon C and Smith CD: A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. Lupus. 7:80–85. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Aouhab Z, Hong H, Felicelli C, Tarplin S and Ostrowski RA: Outcomes of systemic lupus erythematosus in patients who discontinue hydroxychloroquine. ACR Open Rheumatol. 1:593–599. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Costedoat-Chalumeau N, Dunogué B, Morel N, Le Guern V and Guettrot-Imbert G: Hydroxychloroquine: A multifaceted treatment in lupus. Presse Med. 43((6 Pt 2)): e167–e180. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tunks RD, Clowse ME, Miller SG, Brancazio LR and Barker PC: Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents. Am J Obstet Gynecol. 208:64.e1–7. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chen FY, Chen SW, Chen X, Huang JY, Ye Z and Wei JC: Hydroxychloroquine might reduce risk of incident endometriosis in patients with systemic lupus erythematosus: A retrospective population-based cohort study. Lupus. 30:1609–1616. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Yang DH, Leong PY, Sia SK, Wang YH and Wei JC: Long-Term hydroxychloroquine therapy and risk of coronary artery disease in patients with systemic lupus erythematosus. J Clin Med. 8:7962019. View Article : Google Scholar : PubMed/NCBI | |
|
Lu KQ, Zhu ZZ, Wei SR, Zeng HS and Mo HY: Systemic lupus erythematosus complicated with cardiovascular disease. Int J Rheum Dis. 26:1429–1431. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Lo CH, Wei JC, Wang YH, Tsai CF, Chan KC, Li LC, Lo TH and Su CH: Hydroxychloroquine does not increase the risk of cardiac arrhythmia in common rheumatic diseases: A nationwide population-based cohort study. Front Immunol. 12:6318692021. View Article : Google Scholar : PubMed/NCBI | |
|
Lo CH, Wang YH, Tsai CF, Chan KC, Li LC, Lo TH, Wei JC and Su CH: Association of hydroxychloroquine and cardiac arrhythmia in patients with systemic lupus erythematosus: A population-based case control study. PLoS One. 16:e02519182021. View Article : Google Scholar : PubMed/NCBI | |
|
Wu CY, Tan M, Huang JY, Chiou JY and Wei JC: Hydroxychloroquine is neutral in risk of chronic kidney disease in patients with systemsic lupus erythematosus. Ann Rheum Dis. 81:e752022. View Article : Google Scholar : PubMed/NCBI | |
|
Shinjo SK, Bonfá E, Wojdyla D, Borba EF, Ramirez LA, Scherbarth HR, Brenol JC, Chacón-Diaz R, Neira OJ, Berbotto GA, et al: Antimalarial treatment may have a time-dependent effect on lupus survival: Data from a multinational Latin American inception cohort. Arthritis Rheum. 62:855–862. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kariburyo F, Xie L, Sah J, Li N and Lofland JH: Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States. J Med Econ. 23:1–9. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y and Kawahata K: Hydroxychloroquine improves the disease activity and allows the reduction of the corticosteroid dose regardless of background treatment in japanese patients with systemic lupus erythematosus. Intern Med. 58:1257–1262. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, et al: Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 46:1019–1027. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Petri M: Antiphospholipid syndrome. Transl Res. 225:70–81. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Miranda S, Billoir P, Damian L, Thiebaut PA, Schapman D, Le Besnerais M, Jouen F, Galas L, Levesque H, Le Cam-Duchez V, et al: Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction. PLoS One. 14:e02126142019. View Article : Google Scholar : PubMed/NCBI | |
|
Sayar Z, Moll R, Isenberg D and Cohen H: Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and management. Thromb Res. 198:213–221. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Schreiber K, Breen K, Parmar K, Rand JH, Wu XX and Hunt BJ: The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies. Rheumatology (Oxford). 57:120–124. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Müller-Calleja N, Ritter S, Hollerbach A, Falter T, Lackner KJ and Ruf W: Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies. Blood Adv. 2:979–986. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Guo Y, Gao F, Wang X, Pan Z, Wang Q, Xu S, Pan S, Li L, Zhao D and Qian J: Spontaneous formation of neutrophil extracellular traps is associated with autophagy. Sci Rep. 11:240052021. View Article : Google Scholar : PubMed/NCBI | |
|
Boone BA, Murthy P, Miller-Ocuin J, Doerfler WR, Ellis JT, Liang X, Ross MA, Wallace CT, Sperry JL, Lotze MT, et al: Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps. BMC Cancer. 18:6782018. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y, Xu W, Huang S, Li J, Li T, Chen J, Lu Y and Zhang J: Analysis of pregnancy outcomes in patients exhibiting recurrent miscarriage with concurrent low-titer antiphospholipid antibodies. Am J Reprod Immunol. 92:e139402024. View Article : Google Scholar : PubMed/NCBI | |
|
Sciascia S, Hunt BJ, Talavera-Garcia E, Lliso G, Khamashta MA and Cuadrado MJ: The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol. 214:273.e1–273.e8. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Schreiber K, Breen K, Cohen H, Jacobsen S, Middeldorp S, Pavord S, Regan L, Roccatello D, Robinson SE, Sciascia S, et al: HYdroxychloroquine to improve pregnancy outcome in women with AnTIphospholipid antibodies (HYPATIA. Protocol: A multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. Semin Thromb Hemost. 43:562–571. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Mar N, Kosowicz R and Hook K: Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss. J Thromb Thrombolysis. 38:196–200. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Smolen JS, Aletaha D and McInnes IB: Rheumatoid arthritis. Lancet. 388:2023–2038. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Schapink L, van den Ende CHM, Gevers LAHA, van Ede AE and den Broeder AA: The effects of methotrexate and hydroxychloroquine combination therapy vs methotrexate monotherapy in early rheumatoid arthritis patients. Rheumatology (Oxford). 58:131–134. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma TS, Wasko MC, Tang X, Vedamurthy D, Yan X, Cote J and Bili A: Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients. J Am Heart Assoc. 5:e0028672016. View Article : Google Scholar : PubMed/NCBI | |
|
Wu CL, Chang CC, Kor CT, Yang TH, Chiu PF, Tarng DC and Hsu CC: Hydroxychloroquine use and risk of CKD in patients with rheumatoid arthritis. Clin J Am Soc Nephrol. 13:702–709. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe DJ and Bombardier C: Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. Cochrane Database Syst Rev. 2016:CD0102272016.PubMed/NCBI | |
|
Zhang L, Chen F, Geng S, Wang X, Gu L, Lang Y, Li T and Ye S: Methotrexate (MTX) plus hydroxychloroquine versus MTX plus leflunomide in patients with MTX-resistant active rheumatoid arthritis: A 2-year cohort study in real world. J Inflamm Res. 13:1141–1150. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, Lew RA, Cannella AC, Kunkel G, Phibbs CS, et al: Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 369:307–318. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Shi ZC, Fei HP and Wang ZL: Cost-effectiveness analysis of etanercept plus methotrexate vs triple therapy in treating Chinese rheumatoid arthritis patients. Medicine (Baltimore). 99:e166352020. View Article : Google Scholar : PubMed/NCBI | |
|
Østergaard M, van Vollenhoven RF, Rudin A, Hetland ML, Heiberg MS, Nordström DC, Nurmohamed MT, Gudbjornsson B, Ørnbjerg LM, Bøyesen P, et al: Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial. Ann Rheum Dis. 82:1286–1295. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Haridoss M, Sasidharan A, Kumar S, Rajsekar K, Venkataraman K and Bagepally BS: Cost-Utility analysis of TNF-α inhibitors, B cell inhibitors and JAK inhibitors versus csDMARDs for rheumatoid arthritis treatment. Appl Health Econ Health Policy. 22:885–896. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Combe B, Kivitz A, Tanaka Y, van der Heijde D, Simon JA, Baraf HSB, Kumar U, Matzkies F, Bartok B, Ye L, et al: Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: A phase III randomised clinical trial. Ann Rheum Dis. 80:848–858. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Bredemeier M, Duarte ÂL, Pinheiro MM, Kahlow BS, Macieira JC, Ranza R, Miranda JR, Valim V, de Castro GR, Bértolo MB, et al: The effect of antimalarials on the safety and persistence of treatment with biologic agents or Janus kinase inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 63:456–465. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F and Zhong R: Epidemiology of primary Sjögren's syndrome: A systematic review and meta-analysis. Ann Rheum Dis. 74:1983–1989. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Meijer JM, Meiners PM, Slater JJ, Spijkervet FK, Kallenberg CG, Vissink A and Bootsma H: Health-related quality of life, employment and disability in patients with Sjogren's syndrome. Rheumatology (Oxford). 489:1077–1082. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yavuz S, Asfuroğlu E, Bicakcigil M and Toker E: Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren's syndrome. Rheumatol Int. 31:1045–1049. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hernández-Molina G, Valim V, Secco A, Atisha-Fregoso Y, Guerra E, Adrover M, Santos AJ and Catalán-Pellet A: Do antimalarials protect against damage accrual in primary Sjögren's syndrome? Results from a Latin-American retrospective cohort. Clin Exp Rheumatol. 36 (Suppl 112):S182–S185. 2018. | |
|
Yoon CH, Lee HJ, Lee EY, Lee EB, Lee WW, Kim MK and Wee WR: Effect of hydroxychloroquine treatment on dry eyes in subjects with primary Sjögren's Syndrome: A double-blind randomized control study. J Korean Med Sci. 31:1127–1135. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang SQ, Zhang LW, Wei P and Hua H: Is hydroxychloroquine effective in treating primary Sjogren's syndrome: A systematic review and meta-analysis. BMC Musculoskelet Disord. 18:1862017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Zhang T, Guo Z, Pu J, Riaz F, Feng R, Fang X, Song J, Liang Y, Wu Z, et al: The efficiency of hydroxychloroquine for the treatment of primary Sjögren's syndrome: A systematic review and meta-analysis. Front Pharmacol. 12:6937962021. View Article : Google Scholar : PubMed/NCBI | |
|
Sontheimer RD: Aminoquinoline antimalarial therapy in dermatomyositis-are we missing opportunities with respect to comorbidities and modulation of extracutaneous disease activity? Ann Transl Med. 6:1542018. View Article : Google Scholar : PubMed/NCBI | |
|
Olson NY and Lindsley CB: Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol. 16:1545–1547. 1989.PubMed/NCBI | |
|
Bloom BJ, Tucker LB, Klein-Gitelman M, Miller LC and Schaller JG: Worsening of the rash of juvenile dermatomyositis with hydroxychloroquine therapy. J Rheumatol. 21:2171–2172. 1994.PubMed/NCBI | |
|
Jokar M, Mirfeizi Z and Keyvanpajouh K: The effect of hydroxychloroquine on symptoms of knee osteoarthritis: A double-blind randomized controlled clinical trial. Iran J Med Sci. 38:221–226. 2013.PubMed/NCBI | |
|
Singh A, Kotlo A, Wang Z, Dissanayaka T, Das S and Antony B: Efficacy and safety of hydroxychloroquine in osteoarthritis: A systematic review and meta-analysis of randomized controlled trials. Korean J Intern Med. 37:210–221. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Woźniacka A: Antimalarials-old drugs are new again. Postepy Dermatol Alergol. 39:239–244. 2022.PubMed/NCBI | |
|
Martín-Iglesias D, Artaraz J, Fonollosa A, Ugarte A, Arteagabeitia A and Ruiz-Irastorza G: Evolution of retinal changes measured by optical coherence tomography in the assessment of hydroxychloroquine ocular safety in patients with systemic lupus erythematosus. Lupus. 28:555–559. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Mukwikwi ER, Pineau CA, Vinet E, Clarke AE, Nashi E, Kalache F, Grenier LP and Bernatsky S: Retinal Complications in patients with systemic lupus erythematosus treated with antimalarial drugs. J Rheumatol. 47:553–556. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Cramarossa G, Liu HY, Turk MA and Pope JE: Guidelines on prescribing and monitoring antimalarials in rheumatic diseases: A systematic review. Clin Exp Rheumatol. 39:407–412. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Angelakis E, Million M, Kankoe S, Lagier JC, Armougom F, Giorgi R and Raoult D: Abnormal weight gain and gut microbiota modifications are side effects of long-term doxycycline and hydroxychloroquine treatment. Antimicrob Agents Chemother. 58:3342–3347. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ponticelli C and Moroni G: Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf. 16:411–419. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Cairoli E, Danese N, Teliz M, Bruzzone MJ, Ferreira J, Rebella M and Cayota A: Cumulative dose of hydroxychloroquine is associated with a decrease of resting heart rate in patients with systemic lupus erythematosus: A pilot study. Lupus. 24:1204–1209. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tselios K, Gladman DD, Harvey P, Akhtari S, Su J and Urowitz MB: Abnormal cardiac biomarkers in patients with systemic lupus erythematosus and no prior heart disease: A consequence of antimalarials? J Rheumatol. 46:64–69. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sorour AA, Kurmann RD, Shahin YE, Crowson CS, Achenbach SJ, Mankad R and Myasoedova E: Use of hydroxychloroquine and risk of heart failure in patients with rheumatoid arthritis. J Rheumatol. 48:1508–1511. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Chatre C, Roubille F, Vernhet H, Jorgensen C and Pers YM: Cardiac complications attributed to chloroquine and hydroxychloroquine: A systematic review of the literature. Drug Saf. 41:919–931. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Quiñones ME, Joseph JK, Dowell S, Moore HJ, Karasik PE, Fonarow GC, Fletcher RD, Cheng Y, Zeng-Treitler Q, Arundel C, et al: Hydroxychloroquine and risk of long QT syndrome in rheumatoid arthritis: A veterans cohort study with nineteen-year follow-up. Arthritis Care Res (Hoboken). 75:1571–1579. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Tehrani R, Ostrowski RA, Hariman R and Jay WM: Ocular toxicity of hydroxychloroquine. Semin Ophthalmol. 23:201–209. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Yusuf IH, Sharma S, Luqmani R and Downes SM: Hydroxychloroquine retinopathy. Eye (Lond). 31:828–845. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Browning DJ and Lee C: Somatotype, the risk of hydroxychloroquine retinopathy and safe daily dosing guidelines. Clin Ophthalmol. 12:811–818. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Browning DJ and Lee C: Scotoma analysis of 10-2 visual field testing with a white target in screening for hydroxychloroquine retinopathy. Clin Ophthalmol. 9:943–952. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Modi YS and Singh RP: Bull's-eye maculopathy associated with hydroxychloroquine. N Engl J Med. 380:16562019. View Article : Google Scholar : PubMed/NCBI | |
|
Marmor MF, Kellner U, Lai TY, Melles RB and Mieler WF; American Academy of Ophthalmology, : Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology. 123:1386–1394. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wolfe F and Marmor MF: Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken). 62:775–784. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Spinelli FR, Moscarelli E, Ceccarelli F, Miranda F, Perricone C, Truglia S, Garufi C, Massaro L, Morello F, Alessandri C, et al: Treating lupus patients with antimalarials: Analysis of safety profile in a single-center cohort. Lupus. 27:1616–1623. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kellner S, Weinitz S, Farmand G and Kellner U: Cystoid macular oedema and epiretinal membrane formation during progression of chloroquine retinopathy after drug cessation. Br J Ophthalmol. 98:200–206. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Muller R: Systemic toxicity of chloroquine and hydroxychloroquine: Prevalence, mechanisms, risk factors, prognostic and screening possibilities. Rheumatol Int. 41:1189–1202. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Lipner SR and Wang Y: Retrospective analysis of dermatologic adverse events associated with hydroxychloroquine reported to the US food and drug administration. J Am Acad Dermatol. 83:1527–1529. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Coulombe J and Boccara O: Hydroxychloroquine-related skin discoloration. CMAJ. 189:E2122017. View Article : Google Scholar : PubMed/NCBI | |
|
Dos Reis Neto ET, Kakehasi AM, de Medeiros Pinheiro M, Ferreira GA, Marques CDL, da Mota LMH, Dos Santos Paiva E, Pileggi GCS, Sato EI, Reis APMG, et al: Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Adv Rheumatol. 60:322020. View Article : Google Scholar : PubMed/NCBI | |
|
Léger JM, Puifoulloux H, Dancea S, Hauw JJ, Bouche P, Rougemont D and Laplane D: Chloroquine neuromyopathies: 4 cases during antimalarial prevention. Rev Neurol (Paris). 142:746–752. 1986.(In French). PubMed/NCBI | |
|
Pagès M and Pagès AM: Peripheral nerve lesions in chloroquine-induced neuromyopathies. Ann Pathol. 4:289–295. 1984.(In French). PubMed/NCBI | |
|
Doyno C, Sobieraj DM and Baker WL: Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. Clin Toxicol (Phila). 59:12–23. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Casado E, Gratacós J, Tolosa C, Martínez JM, Ojanguren I, Ariza A, Real J, Sanjuán A and Larrosa M: Antimalarial myopathy: An underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis. 65:385–390. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Abdel-Hamid H, Oddis CV and Lacomis D: Severe hydroxychloroquine myopathy. Muscle Nerve. 38:1206–1210. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Jafri K, Zahed H, Wysham KD, Patterson S, Nolan AL, Bucknor MD and Chaganti RK: Antimalarial myopathy in a systemic lupus erythematosus patient with quadriparesis and seizures: A case-based review. Clin Rheumatol. 36:1437–1444. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chary MA, Barbuto AF, Izadmehr S, Hayes BD and Burns MM: COVID-19: Therapeutics and their toxicities. J Med Toxicol. 16:284–294. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Gasmi A, Peana M, Noor S, Lysiuk R, Menzel A, Benahmed AG and Bjørklund G: Chloroquine and hydroxychloroquine in the treatment of COVID-19: The never-ending story. Appl Microbiol Biotechnol. 105:1333–1343. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W and Wang M: Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 6:162020. View Article : Google Scholar : PubMed/NCBI | |
|
Martinez GP, Zabaleta ME, Di Giulio C, Charris JE and Mijares MR: The role of chloroquine and hydroxychloroquine in immune regulation and diseases. Curr Pharm Des. 26:4467–4485. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ye Q, Wang B and Mao J: The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 80:607–613. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Bajpai J, Pradhan A, Singh A and Kant S: Hydroxychloroquine and COVID-19-A narrative review. Indian J Tuberc. 67((4S)): S147–S154. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, et al: Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 56:1059492020. View Article : Google Scholar : PubMed/NCBI | |
|
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J, Mailhe M, Doudier B, Aubry C, Amrane S, et al: Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 34:1016632020. View Article : Google Scholar : PubMed/NCBI | |
|
Sarhan RM, Harb HS, Warda AE, Salem-Bekhit MM, Shakeel F, Alzahrani SA, Madney YM and Boshra MS: Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 patients. J Infect Public Health. 15:116–122. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Réa-Neto Á, Bernardelli RS, Câmara BMD, Reese FB, Queiroga MVO and Oliveira MC: An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients. Sci Rep. 11:90232021. View Article : Google Scholar : PubMed/NCBI | |
|
Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, Damiani LP, Marcadenti A, Kawano-Dourado L, Lisboa T, et al: Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 383:2041–2052. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ibáñez S, Martínez O, Valenzuela F, Silva F and Valenzuela O: Hydroxychloroquine and chloroquine in COVID-19: Should they be used as standard therapy? Clin Rheumatol. 39:2461–2465. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zang Y, Han X, He M, Shi J and Li Y: Hydroxychloroquine use and progression or prognosis of COVID-19: A systematic review and meta-analysis. Naunyn Schmiedebergs Arch Pharmacol. 394:775–782. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ and White CM: Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: A living systematic review. Ann Intern Med. 173:287–296. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Singh H, Chauhan P and Kakkar AK: Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead. Eur J Pharmacol. 890:1737172021. View Article : Google Scholar : PubMed/NCBI |
